Delivery Order SPE2DB22D3004-SPE2DB25FSD87
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, with an ultimate completion date of September 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The pharmaceutical products will be delivered to AmerisourceBergen's corporate headquarters location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The contract is performed from the company's corporate...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,343.59 on August 18, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 9, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors, valued at $2,343.59, with an ultimate completion date of September 9, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 potential value through December 2026. The place...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors with an ultimate completion date of September 11, 2025. This competitive award was issued under a firm fixed-price contract structure with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 through December 2026. The award carries no set-aside designation and was competitively...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,687.18 for Tezspire 210 mg/1.91 mL pen injectors, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment of severe asthma, representing the type of high-value...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with completion targeted for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $2,343.59 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors on August 12, 2025, with completion scheduled for September 3, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitive award to the major pharmaceutical distributor for a specialized biologic medication used in the treatment of severe asthma. The contract is being performed at AmerisourceBergen's corporate...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSD87Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of September 16, 2025. The contract was competitively awarded without set-aside designation and operates under a firm fixed price structure. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The prime IDC enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. Tezspire is a biologic asthma treatment that aligns with the company's extensive portfolio of specialty medications and brand-name drugs delivered through the DLA Medical Supply Chain to support federal healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/25/25 |